Top Hedge Funds Love These 5 Big Blue-Chip Dividend-Paying Stocks
These stocks make good sense for long-term patient investors that have a growth and income total return bias in their portfolios.
These stocks make good sense for long-term patient investors that have a growth and income total return bias in their portfolios.
The top analyst upgrades, downgrades and initiations seen on Tuesday, February 23, include Annaly Capital Management, Barrick Gold, Cheniere Energy, Fitbit, Dean Foods, Groupon, SolarCity, Twitter and U.S. Steel.
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.
The top analyst upgrades, downgrades and initiations seen on Monday, February 22, include AbbVie, Deere, Expedia, Hewlett Packard Enterprise, JPMorgan and Phillips 66.
For worried investors that need an income stream, all these top stocks make good sense for growth and income portfolios.
One thing that the recent sell-off has accomplished is to take top companies residing in the Jefferies Franchise Picks list to levels not seen in some time.
The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them for political…
AbbVie reported mixed fourth-quarter financial results after the markets closed Thursday.
AbbVie is scheduled to report its fourth-quarter financial results before the markets open Friday.
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
The Wall Street firms we cover are well aware of investor anxiety, yet they, unlike financial media talking heads, realize investors can’t just go to cash with a snap of their fingers.
The short interest data have been released for the December 31 settlement date. For most of the selected pharmaceutical stocks short interest was up.
In a new research note, Jefferies makes the case that earnings could give a lift to the sagging market, and with low expectations, the lift could be solid.
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.